Media coverage
3
Media coverage
Title Divarasib Shows Activity in Patients With KRAS-Mutated Solid Tumors Media name/outlet Cancer Therapy advisor Media type Web Country/Territory United Kingdom Date 5/09/23 Description The KRASG12C inhibitor divarasib can produce responses in patients with solid tumors, according to research published in The New England Journal of Medicine. URL https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/divarasib-shows-activity-in-patients-with-kras-mutated-solid-tumors/ Persons Matthew Krebs Title Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors Media name/outlet OncLive Media type Web Country/Territory United Kingdom Date 5/09/23 Description Treatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036) led to durable responses with a tolerable safety profile in patients with a variety of solid tumors harboring a KRAS G12C mutation, according to findings from a phase 1 trial (NCT04449874) published in the New England Journal of Medicine. URL https://www.onclive.com/view/divarasib-displays-early-phase-activity-in-kras-g12c-mutant-solid-tumors Persons Matthew Krebs Title Roche's divarasib scores Phase I win in Kras-mutated solid tumours Media name/outlet Pharmalive Media type Web Country/Territory United Kingdom Date 24/08/23 Description Roche's Genentech on Thursday released early-stage data on its KRAS inhibitor, divarasib, as it hopes to join Amgen and Mirati in the potential blockbuster cancer market. URL https://www.pharmalive.com/roches-divarasib-scores-phase-i-win-in-kras-mutated-solid-tumors/ Persons Matthew Krebs